This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
FULPHILA 6 MG SOLUCION INYECTABLE EN JERINGA PRECARGADA — Description, Dosage, Side Effects | PillsCard
OTC
FULPHILA 6 MG SOLUCION INYECTABLE EN JERINGA PRECARGADA
INN: FULPHILA
Data updated: 2026-04-11
Available in:
🇩🇪🇬🇧🇪🇸
Form
—
Dosage
—
Route
—
Storage
—
About This Product
Manufacturer
Biosimilar Collaborations Ireland Limited
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
(ES)
Source
CIMA_ES
USDailyMed:Pegfilgrastim
AU:B3
L03AA13(WHO)
AU:S4(Prescription only)CA:℞-only/ Schedule DUK:POM(Prescription only)US:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only)
N-(3-Hydroxypropyl)Methionylcolony-stimulating Factor (human), 1-Ether with .Alpha.-Methyl-.Omega.-Hydroxypoly(Oxyethylene)
208265-92-3Y
6969
DB00019Y
none
3A58010674
D06889Y
ChEMBL1201568N
Pegfilgrastim, sold under the brand nameNeulastaamong others, is aPEGylatedform of the recombinant humangranulocyte colony-stimulating factor(GCSF) analogfilgrastim.It serves to stimulate the production of white blood cells (neutrophils).Pegfilgrastim was developed byAmgen.
Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy.
Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours).
Pegfilgrastim was approved for medical use in the United States in January 2002, in the European Union in August 2002, and in Australia in September 2002.It is on theWorld Health Organization's List of Essential Medicines.
